Smart healthcare for gastric cancer patients starting immunotherapy
Part of Cancer, Digestive system clinical trials.
This study is testing whether a smart healthcare program that includes personalized education and home exercise can help people with advanced gastric cancer who are starting immunotherapy. The goal is to reduce frailty, manage side effects, and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with advanced gastric cancer (stage III or IV)
- You are about to start your first round of immunotherapy
- You have not had another type of cancer in the last five years
- You do not have dementia, and you can communicate clearly
- You have no recent serious heart or lung problems, broken bones in the last three months, or cancer spread to your bones
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses artificial intelligence to analyze CT scans, blood, and tumor tissue to predict how well your cancer will respond to chemotherapy and immunotherapy before surgery. It aims to personalize treatment for locally advanced stomach or gastroesophageal junction cancer.
This trial studies whether blood tests before treatment can predict side effects from immunotherapy (PD-1/PD-L1 inhibitors) in people with gastric cancer. If you are about to start this type of treatment, your participation could help doctors manage side effects better.
This study looks at markers in your tumor to predict how well immunotherapy might work for you. It aims to create a model that helps doctors choose the best treatment for advanced gastric cancer.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs before surgery for people with resectable gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial studies a new immunotherapy drug (SHR-1701) combined with standard chemoradiotherapy for people with advanced stomach or esophagus cancer that cannot be surgically removed. The goal is to see if adding this immune treatment helps control the tumor better than standard treatments alone.
This Phase 1/2 trial tests an immune-based treatment for advanced (Stage III–IV) GI cancer. You may be able to join only if your tumor shows certain “marker” proteins on special lab staining, and your blood and organ tests meet study limits.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.